Navigation Links
ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
Date:3/18/2009

ADDISON, Texas, March 18 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) announced that clinical evidence on the treatment of diabetic foot ulcers, and data on the use of its patented Nanoflex(TM) Technology for Therapeutic Delivery will be presented at the annual DFCon Global Meeting in Los Angeles, California March 19-21. The work will be presented on posters that will be on display during the meeting.

Clinical evidence will be presented on a poster titled, "Nanoparticulate Aggregate Wound Dressing in the Management of Soft Tissue Wounds". This research details the application of Altrazeal(TM) in the treatment of a patient following radical debridement of necrotizing fasciitis. Commenting on the work, DFCon organizer and one of the study's co-authors, Dr. David Armstrong, Professor of Surgery and Director, Southern Arizona Limb Salvage Alliance (SALSA) University of Arizona College of Medicine stated, "We have been provisionally impressed with this modality. We believe that marrying such technologies with an aggressive team effort might well prove helpful in reducing the unnecessarily high rate of amputations in the USA and worldwide."

Further clinical evidence for the use of Altrazeal(TM) in treating diabetic foot ulcers is detailed in a poster titled "Properties of a Novel Powder Wound Dressing and Clinical Experience in Diabetic Foot Ulcers." This work presents the use of Altrazeal(TM) Transforming Powder Dressing in the treatment of four separate ulcers in diabetic patients. The treatments were performed by Gregory Bohn, MD FACS, the Medical Director of Trinity Center for Wound Care and Hyperbaric Medicine in Bettendorf, IA., Sid Sharma, DPM FAPWCA, and Gianni Persich, DPM FAPWCA both at All Country Podiatry in NY. Four cases of ulcers present on heel, toe or ankle are shown and each was treated with Altrazeal(TM) following wound bed preparation. For all four patients, the time to healing was between one and four weeks and one patient's ulcer had been present in stasis for 24 weeks prior to Altrazeal(TM) treatment. Commenting on the results, Dr. Persich stated "Altrazeal(TM) represents a new generation of smart dressings which will greatly aid in treating these complex wounds."

A third poster titled "Nanoflex(TM) Technology Applied to the Development of Advanced Controlled Release Dressings" highlights the flexibility of ULURU's patented technology in the delivery of molecules both in the laboratory and in vivo animal models. Data is presented on the delivery of small molecule therapeutics and the delivery of the therapeutic protein, VEGF to a wound bed in a porcine model resulting in dramatic differences in the effects of controlled release on the healing endpoint. Dr. John St. John, Vice President of Research and Development for ULURU Inc. stated, "These results demonstrate evidence of the capability of our Nanoflex(TM) technology to allow the development of medical devices to target the specific phases of the wound healing cycle."

Abstracts for these posters are available on the DFCon website at http://www.dfcon.com/abstracts.html.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Nanoflex(TM) Aggregate technology. For further information about ULURU Inc., please visit our website at www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the benefits, effectiveness, and suitability of Altrazeal(TM), and the success of our clinical efforts. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 and quarterly report on Form 10-Q for the quarter ended September 30, 2008, and other reports filed by us with the Securities and Exchange Commission.

    Contact: Company
    Renaat Van den Hooff
    President & CEO
    Terry K. Wallberg
    Vice President & CFO
    (214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
3. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
4. Quark Pharmaceuticals Presents at Asia TIDES Conference
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
7. Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma
8. Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
9. Spectral presents data on the clinical utility of EAA(TM) at 13th Annual Critical Care for Endotoxemia conference in Japan
10. Results of NeuroThera Effectiveness and Safety Trial - 2 (NEST-2) Presented at International Stroke Conference 2009
11. Atritech to Participate in Late-Breaking Clinical Trial Presentation at American College of Cardiology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... KONG , Feb. 9, 2016 Athenex, Inc. ... Athenex as Vice President of Corporate Strategy and Business Development ... MSc, MBA has joined as Senior Director and Deputy Head of Clinical ... . Simon Pedder stated, "Athenex has ... for a while. Coupled together with their unique business model ...
(Date:2/9/2016)... 2016  The Parenteral Drug Association, Inc. (PDA), ... manufacturing sterile drug products, today announced the publication ... – With link to Comparison Spreadsheet. The ... U.S. FDA, the EU, the Pharmaceutical Inspection Convention/Scheme ... --> --> PDA,s Global Sterile ...
(Date:2/8/2016)... 2016 Respiratory Devices - Medical Devices ... Devices sector report, " Respiratory Devices - Medical ... of Respiratory Devices currently in pipeline stage. ... products with comparative analysis of the products at ... players involved in the pipeline product development. It ...
Breaking Medicine Technology:
(Date:2/9/2016)... G.A. (PRWEB) , ... February 09, 2016 , ... ... and grout cleaning and sealing company , is proud to announce that many ... their superior levels of customer service. The hard surface restoration franchises received customer ...
(Date:2/8/2016)... , ... February 08, 2016 , ... CURE Media ... has officially launched the Multiple Myeloma Heroes Awards event , which will annually ... the lives of patients with MM. The MM Heroes Awards nomination process ...
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie ... celebrates the beginning of a new charity campaign. As part of their ongoing ... Advocates (CASA). In the belief that children deserve a voice, and in the ...
(Date:2/8/2016)... New York, NY (PRWEB) , ... February 08, 2016 , ... ... handles are too much to handle, you are not alone. According to the Center ... conditions include heart disease, stroke, type 2 diabetes and certain types of cancer, some ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local insurance agency Dennis ... FL area, has initiated a fundraiser for a two year old little girl ... after Christmas. To support this beautiful child who is facing life’s journey without ...
Breaking Medicine News(10 mins):